Literature DB >> 24288046

Survey about tolerance of the AS03-adjuvanted H1N1 influenza vaccine in children with rheumatic diseases.

C Sengler1, M Niewerth, T Kallinich, A Nimtz-Talaska, M Haller, H-I Huppertz, K Minden.   

Abstract

The objective of this study is to evaluate complications and changes in health status (disease activity and flare) in response to the AS03-adjuvanted H1N1 vaccine in children with rheumatic diseases. We conducted a nationwide survey addressing paediatric rheumatology sites who participated in the national paediatric rheumatology database. Ninety patients were documented-38 % under treatment with biologicals-of whom 18 % suffered from complications (10 % local and 8 % systemic) with no relevant changes in median disease activity or flare rate during 4 weeks following the vaccination. The adjuvanted H1N1 influenza vaccine seems to be adequately tolerated in children with rheumatic diseases.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24288046     DOI： 10.1007/s10067-013-2435-8

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN： 0770-3198            Impact factor:   2.980


  11 in total

1.  Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial.

Authors:  François Roman; Tejaswini Vaman; Beatrice Gerlach; Andre Markendorf; Paul Gillard; Jeanne-Marie Devaster
Journal:  Vaccine       Date:  2009-12-22       Impact factor: 3.641

2.  Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center study.

Authors:  Cem Gabay; Michael Bel; Christophe Combescure; Camillo Ribi; Sara Meier; Klara Posfay-Barbe; Stéphane Grillet; Jörg D Seebach; Laurent Kaiser; Werner Wunderli; Pierre-André Guerne; Claire-Anne Siegrist
Journal:  Arthritis Rheum       Date:  2011-06

3.  Humoral immunity in juvenille rheumatoid arthritis.

Authors:  H M Höyeraal; O J Mellbye
Journal:  Ann Rheum Dis       Date:  1974-05       Impact factor: 19.103

4.  Immunogenicity of influenza vaccine in children with pediatric rheumatic diseases receiving immunosuppressive agents.

Authors:  Chikara Ogimi; Risa Tanaka; Akihiko Saitoh; Tsutomu Oh-Ishi
Journal:  Pediatr Infect Dis J       Date:  2011-03       Impact factor: 2.129

5.  Effective seroconversion and safety following the pandemic influenza vaccination (anti-H1N1) in patients with juvenile idiopathic arthritis.

Authors:  N E Aikawa; L M A Campos; C Goldenstein-Schainberg; C G S Saad; A C Ribeiro; C Bueno; A R Precioso; M do C Timenetsky; C A A Silva; E Bonfá
Journal:  Scand J Rheumatol       Date:  2012-09-20       Impact factor: 3.641

6.  Influenza vaccination in children with chronic rheumatic diseases and long-term immunosuppressive therapy.

Authors:  F Kanakoudi-Tsakalidou; M Trachana; P Pratsidou-Gertsi; E Tsitsami; V Kyriazopoulou-Dalaina
Journal:  Clin Exp Rheumatol       Date:  2001 Sep-Oct       Impact factor: 4.473

7.  Safety and efficacy of meningococcal c vaccination in juvenile idiopathic arthritis.

Authors:  Evelien Zonneveld-Huijssoon; Arash Ronaghy; Marion A J Van Rossum; Ger T Rijkers; Fiona R M van der Klis; Elisabeth A M Sanders; Patricia E Vermeer-De Bondt; Arno W Hoes; Jan Jaap van der Net; Carla Engels; Wietse Kuis; Berent J Prakken; Maarten J D Van Tol; Nico M Wulffraat
Journal:  Arthritis Rheum       Date:  2007-02

8.  Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study.

Authors:  Claire S Waddington; W T Walker; C Oeser; A Reiner; T John; S Wilkins; M Casey; P E Eccleston; R J Allen; I Okike; S Ladhani; E Sheasby; K Hoschler; N Andrews; P Waight; A C Collinson; P T Heath; A Finn; S N Faust; M D Snape; E Miller; A J Pollard
Journal:  BMJ       Date:  2010-05-27

9.  Safety of measles, mumps and rubella vaccination in juvenile idiopathic arthritis.

Authors:  Marloes W Heijstek; Gecilmara C S Pileggi; Evelien Zonneveld-Huijssoon; Wineke Armbrust; Esther P A H Hoppenreijs; Cuno S P M Uiterwaal; Wietse Kuis; Nico M Wulffraat
Journal:  Ann Rheum Dis       Date:  2007-02-06       Impact factor: 19.103

10.  Influenza immunization in children with chronic arthritis: a prospective study.

Authors:  P N Malleson; J L Tekano; D W Scheifele; J M Weber
Journal:  J Rheumatol       Date:  1993-10       Impact factor: 4.666
View more
  3 in total

Review 1.  Vaccination recommendations for adult patients with rheumatic diseases.

Authors:  Mine Durusu Tanrıöver; Servet Akar; Nuran Türkçapar; Ömer Karadağ; İhsan Ertenli; Sedat Kiraz
Journal:  Eur J Rheumatol       Date:  2015-10-28

2.  Vaccinations Do Not Increase Arthritis Flares in Juvenile Idiopathic Arthritis: A Study of the Relationship between Routine Childhood Vaccinations on the Australian Immunisation Schedule and Arthritis Activity in Children with Juvenile Idiopathic Arthritis.

Authors:  Naba M Alfayadh; Peter J Gowdie; Jonathan D Akikusa; Mee Lee Easton; Jim P Buttery
Journal:  Int J Rheumatol       Date:  2020-08-04

3.  Immunogenicity and safety of influenza vaccination in patients with juvenile idiopathic arthritis on biological therapy using the microneutralization assay.

Authors:  M S Camacho-Lovillo; A Bulnes-Ramos; W Goycochea-Valdivia; L Fernández-Silveira; E Núñez-Cuadros; O Neth; P Pérez-Romero
Journal:  Pediatr Rheumatol Online J       Date:  2017-08-07       Impact factor: 3.054
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.